Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
24/07/26	ILA 173.50	+2.18%	89,117
22/07/26	ILA 169.80	-1.22%	272,019
21/07/26	ILA 171.90	-5.39%	92,334
20/07/26	ILA 181.70	+5.33%	175,603

Delayed Quote TEL AVIV STOCK EXCHANGE

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - TEL AVIV STOCK EXCHANGE Other stock markets 08:44:24 24/07/26 pm AEST			5-day change	1st Jan Change
173.50 ^ILa	+2.18%		+0.58%	-42.28%

23/07	Evogene Ltd. and Eleo Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule Pcsk9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases	CI
22/07	Evogene, ELEO Collaborating to Develop Oral PCSK9 Inhibitors	MT

Market Cap	5.93M 1.81B 5.21M 4.84M 4.44M 8.36M 573M 8.48M 57.45M 22.47M 281M 22.26M 21.79M 971M	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	5.93M 1.81B 5.21M 4.84M 4.44M 8.36M 573M 8.48M 57.45M 22.47M 281M 22.26M 21.79M 971M	EV / Sales 2026 *	4x	EV / Sales 2027 *	2.28x
Free-Float	82.98%	Yield 2026 *	-	Yield 2027 *	-

23/07	Evogene Ltd. and Eleo Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule Pcsk9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases	CI
22/07	Evogene, ELEO Collaborating to Develop Oral PCSK9 Inhibitors	MT
11/07	L.I.A. Pure Capital Sends Letter to Evogene	CI
09/07	Evogene Ltd. and Blavatnik Center For Drug Discovery at Tel Aviv University Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery	CI
24/06	Evogene Ltd. And Google Cloud Announces Major Milestone In Collaboration Advancing ChemPass AI Toward Autonomous Small Molecule Discovery And Optimization	CI
02/06	Biomica Completes Phase 1 Clinical Study of Bmc128 in Combination with Nivolumab	CI
21/05	Evogene Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
21/05	Evogene Ltd., Q1 2026 Earnings Call, May 20, 2026
20/05	Evogene Ltd files for offering of 2.45 million ordinary shares by selling shareholder SEC filing	RE
19/05	Evogene Ltd.'S Subsidiary Ag Plenus Ltd. and Bayer Ag to Discontinue Their Herbicide Development Project	CI
25/04	Evogene's Casterra unit eyes castor crop growth in Brazil	RE
03/04	Evogene reports receipt of Nasdaq minimum bid price notification	RE
03/04	Evogene Gets Nasdaq Minimum Bid Price Notification	MT

02/10/23	Alliance Global Starts Evogene at Buy With $1.85 Price Target	MT
19/08/23	Lake Street Adjusts Evogene's Price Target to $3 From $2, Keeps Buy Rating	MT
30/07/21	EVOGENE : Aegis Capital Starts Evogene at Buy	MT
01/12/20	EVOGENE : Cantor Fitzgerald Starts Evogene at Overweight With $9 Price Target	MT

Evogene Ltd. Stock

Stocks

EVGN

IL0011050551

Biotechnology & Medical Research

Valuation: Evogene Ltd.

Chart: Evogene Ltd.

Latest news : Evogene Ltd.

Last Transcript: Evogene Ltd.

Analysts' recommendations: Evogene Ltd.

Press Releases: Evogene Ltd.

News in other languages: Evogene Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Evogene Ltd.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

22/07	Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases	PR
08/07	Evogene : and Tel Aviv University’s Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery	PU
02/06	Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica	PR
20/05	Evogene : Q1 2026 Consolidated Financial Statements	PU
20/05	Evogene: Q1 Earnings Snapshot	AQ

1 day	+2.18%
1 week	+0.58%
Current month	+35.97%
1 month	+43.74%
3 months	-29.13%
6 months	-46.71%
Current year	-42.28%

1 week	156	194.1
1 month	116	194.1
Current year	115.1	410
1 year	115.1	478.7
3 years	115.1	3,954
5 years	115.1	10,430
10 years	115.1	33,500

Manager	Title	Age	Since
Ofer Haviv CEO	Chief Executive Officer	60	01/12/2004
Gabi Tarcic PRN	Corporate Officer/Principal	-	-
Polina Ravzin PRN	Corporate Officer/Principal	-	01/01/2022

Director	Title	Age	Since
Ofer Haviv BRD	Director/Board Member	60	-
Leon Recanati BRD	Director/Board Member	77	03/06/2010
Sarit Firon CHM	Chairman	60	01/06/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/4/26	Polina Ravzin	Other	Executive/Senior Manager	20,000	0.2294%
18/3/26	Ilia Zhidkov	Other	Chief Technology Officer	57,750	0.6624%
18/3/26	Sarit Firon	Other	Director	18,900	0.2168%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EVOGENE LTD.	+2.18%	+0.58%	-60.91%	-95.66%	5.93M
LONZA GROUP AG	+1.07%	-3.49%	-3.35%	+11.75%	46.86B
REVOLUTION MEDICINES, INC.	+0.25%	+1.65%	+399.22%	+647.65%	40.23B
BEONE MEDICINES AG	-0.27%	+4.45%	+11.81%	+60.81%	36.23B
IQVIA HOLDINGS INC.	+0.35%	+0.87%	+4.46%	-10.31%	34.72B
CELLTRION, INC.	+3.14%	+1.02%	+4.76%	+40.92%	27.89B
MEDPACE HOLDINGS, INC.	-0.73%	+11.84%	+34.39%	+134.44%	16.79B
ASCENDIS PHARMA A/S	+0.47%	-2.74%	-	-	16.74B
EUROFINS SCIENTIFIC SE	+0.42%	-5.52%	-3.43%	+9.10%	13.12B
ICON PUBLIC LIMITED COMPANY	-2.68%	-2.49%	-11.36%	-34.51%	12.7B
Average	+0.42%	+0.80%	+41.73%	+84.91%	24.53B
Weighted average by Cap.	+0.48%	+0.91%	+74.41%	+137.95%

	2026 *	2027 *
Net sales	1.48M 452M 1.3M 1.21M 1.11M 2.09M 143M 2.12M 14.37M 5.62M 70.22M 5.57M 5.45M 243M	2.6M 792M 2.28M 2.12M 1.95M 3.66M 251M 3.72M 25.18M 9.85M 123M 9.76M 9.55M 425M
Net income	-16.69M -5.08B -14.65M -13.63M -12.5M -23.51M -1.61B -23.86M -162M -63.21M -790M -62.62M -61.29M -2.73B	-13.92M -4.24B -12.22M -11.36M -10.43M -19.6M -1.34B -19.9M -135M -52.71M -658M -52.22M -51.11M -2.28B
Net Debt	-	-